Long-term clinical benefits of tacrolimus eye drops are seen in ocular inflammation, suggesting a safer treatment option.
The 0.015% tacrolimus/HPβCD formulation proves efficacy, and safety over 12 months for the treatment of diverse ocular inflammatory conditions, delivering sustained clinical stability and patient-reported benefits with reduced steroid reliance.
No takes yet. Share an insight, caveat, or question.
Puente-Iglesias et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: